Roivant Sciences Ltd. ROIV
Regular-session close
After hours · Nov 20, 6:34 PM ET
- YTD
- +78.13%
- 1 year
- +90.70%
5D -0.69 (-1.72%)
- Market cap
- 28.01B
- Revenue (ttm)
- 41.08M
- EPS (ttm)
- -0.65
- Shares out
- 724.56M
- Forward P/E
- -26.98
- YTD return
- +78.13%
- 1-year return
- +90.70%
- 50-day average
- 37.22
- 200-day average
- 32.65
- Enterprise value
- 24.70B
- Volume
- 3.97M
- Avg volume
- 8.16M
- Open
- 38.86
- Previous close
- 38.96
- Day's range
- 38.46 – 39.51
- 52-week range
- 19.96 – 42.50
- Beta
- 1.20
- Analysts
- Strong Buy
- Price target
- 50.82 (+31.5%)
- Earnings date
- Feb 5, 2027
Key statistics
- Price / sales
- 681.76
- Price / book
- 6.96
- Revenue growth
- 2135.60%
- Free cash flow
- -358.86M
- Total cash
- 4.21B
- Total debt
- 106.57M
- Return on equity
- -8.54%
- Short % of float
- 8.52%
Fundamental scorecard
4 of 25 checks passed on ROIV’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 42.00
- Target (mean)
- 50.82
- Target (high)
- 62.00
- Strong buy2
- Buy9
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 5, 2027
Expected Feb 5, 2027. Consensus EPS estimate -0.44866.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 5, 2027 | Dec 30, 2026 | -0.36 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.36664 | -0.27 | +0.10 | +26.36% |
| Aug 6, 2026 | Jun 30, 2026 | -0.29962 | -0.33 | -0.03 | -10.14% |
| May 20, 2026 | Mar 31, 2026 | -0.28931 | -0.2792 | +0.01 | +3.49% |
| Feb 6, 2026 | Dec 31, 2025 | -0.29954 | -0.24 | +0.06 | +19.88% |
| Nov 10, 2025 | Sep 30, 2025 | -0.3198 | -0.20193 | +0.12 | +36.86% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 28, 2026 | Citigroup | main | Buy | Buy |
| Oct 12, 2026 | Wolfe Research | down | Outperform | Peer Perform |
| Sep 17, 2026 | Stifel | init | — | Buy |
| Sep 9, 2026 | TD Cowen | main | Buy | Buy |
| Sep 9, 2026 | Guggenheim | main | Buy | Buy |
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- roivant.com
News
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why
Wall Street Analysts Think Montes Archimedes Acquisition (ROIV) Could Surge 29.62%: Read This Before Placing a Bet
126,491 Shares in Roivant Sciences Ltd. $ROIV Bought by Edgestream Partners L.P.
David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $48
Nvidia To $300? Here Are 10 Top Analyst Forecasts For Tuesday HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $48
Roivant Sciences Q2 2027 Earnings Call Transcript
KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test
Your note
Sign in to keep a note on ROIV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GLINE MATTHEW | Chief Executive Officer | Sale | Apr 15, 2026 | 16,736,100 |
| GOLD DANIEL ALLEN | Director | Sale | Nov 16, 2026 | 0 |
| KUMAR RAKHI | Officer | Conversion of Exercise of derivative security | Feb 12, 2025 | 163,264 |
| MANCHESTER KEITH S | Director | Sale | Nov 16, 2026 | 0 |
| OREN ILAN | Director | Stock Award(Grant) | Oct 22, 2026 | 124,490 |
| PULIK RICHARD | Chief Financial Officer | Conversion of Exercise of derivative security | Nov 10, 2026 | 222,046 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 11.81% | 85,575,553 | 3.31B | Sep 29, 2026 |
| Blackrock Inc. | 8.54% | 61,879,232 | 2.39B | Sep 29, 2026 |
| Morgan Stanley | 5.33% | 38,603,606 | 1.49B | Sep 29, 2026 |
| QVT Financial LP | 3.27% | 23,723,074 | 917.02M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 3.19% | 23,127,563 | 894.00M | Sep 29, 2026 |
| State Street Corporation | 3.09% | 22,399,587 | 865.86M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.22% | 23,359,928 | 902.98M | Sep 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 2.66% | 19,297,013 | 745.93M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.21% | 15,987,737 | 618.01M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.59% | 11,546,280 | 446.32M | Jun 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P MidCap Momentum ETF | 0.95% | 6,900,746 | 266.75M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.93% | 6,740,514 | 260.55M | Sep 29, 2026 |
